Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
1. Royalty Pharma commits up to $300 million for obexelimab's development. 2. Obexelimab targets IgG4-related disease, with potential FDA approval by 2027. 3. Funding enhances Zenas BioPharma's capabilities for a commercial launch. 4. Obexelimab has shown promising trial results for autoimmune diseases. 5. Future payments depend on trial success and FDA approvals.